Sugi Predict

Sugi Predict / Compounds / SCHEMBL475746

SCHEMBL475746

SCHEMBL475746

COC(=O)c1cc(OC)cc(C(=O)OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.61
▸ CA2 P00918 2/20 0.61
▸ CA12 O43570 1/20 0.58
▸ CA7 P43166 1/20 0.58
▸ CA9 Q16790 1/20 0.58
▸ CA14 Q9ULX7 1/20 0.58
▸ KDM4E B2RXH2 5/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ POLB P06746 3/20 0.56
▸ GAA P10253 3/20 0.56
▸ LMNA P02545 1/20 0.56
▸ NFKB1 P19838 1/20 0.56
▸ XDH P47989 1/20 0.56
▸ GFER P55789 1/20 0.56
▸ NFKB2 Q00653 1/20 0.56
▸ RELA Q04206 1/20 0.56
▸ FUT7 Q11130 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 0.95 CA1 (0.61) CA1CA2CA12CA7CA9
SCHEMBL11264625 0.92 CA1 (0.53) CA1CA2CA12CA7CA9
SCHEMBL56890 0.92 KDM4E (0.55) CA1CA2CA12CA7CA9
SCHEMBL1708875 0.90 PARP1 (0.55) CA1CA2CA12CA7CA9
SCHEMBL28904089 0.90 KDM4E (0.53) CA1CA2CA12CA7CA9
SCHEMBL5226850 0.90 CA1 (0.52) CA1CA2CA12CA7CA9
SCHEMBL147169 0.87 CA1 (0.71) CA1CA2CA12CA7CA9
SCHEMBL988746 0.87 CA1 (0.53) CA1CA2CA12CA7CA9
SCHEMBL55814 0.87 CA1 (0.73) CA1CA2CA12CA7CA9
SCHEMBL3554201 0.87 CA1 (0.48) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103980256-B A kind of preparation method of dinitrogen oxyradical and structural characterization TIANJIN NORMAL UNIVERSITY (CN) 2016-01-13 — — CN claimed
CN-103980256-A Preparation method of novel dinitrooxy radical, and structure characterization of novel dinitrooxy radical UNIV TIANJIN NORMAL 2014-08-13 — — CN claimed
WO-2025001408-A1 PHOSPHORUS-CONTAINING OR SULFUR-CONTAINING MACROCYCLIC PYRAZOLOPYRIMIDINE COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2025-01-02 — — WO disclosed
WO-2024199063-A1 PHOSPHORUS OR SULFUR-CONTAINING MACROCYCLE AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 — — WO disclosed
CN-115368239-B Synthesis and pharmaceutical application of cinnamate derivative 南开大学 2024-04-26 — — CN disclosed
CN-114539094-B Compound with anti-tumor activity and preparation method and application thereof 厦门大学 2023-06-30 — — CN disclosed
CN-115368239-A Synthesis of cinnamate derivative and pharmaceutical application thereof 南开大学 2022-11-22 — — CN disclosed
CN-114539094-A Compound with anti-tumor activity and preparation method and application thereof 厦门大学 2022-05-27 — — CN disclosed
US-20220127605-A1 NUCLEIC ACID CONJUGATE KYOWA KIRIN CO., LTD. (JP) 2022-04-28 — — US disclosed
US-11095129-B2 Capacitor based power system and unmanned vehicle with the capacitor based power system thereof CAPACITOR SCIENCES INCORPORATED (US) 2021-08-17 — — US disclosed
US-11092142-B2 Plasma electric propulsion device CAPACITOR SCIENCES INCORPORATED (US) 2021-08-17 — — US disclosed
US-20020115092-A1 Energy transfer labels with mechanically linked fluorophores THE SCRIPPS RESEARCH INSTITUTE 2002-08-22 — — US disclosed
WO-2002040701-A2 ENERGY TRANSFER LABELS WITH MECHANICALLY LINKED FLUOROPHORES THE SCRIPPS RESEARCH INSTITUTE (US) 2002-05-23 — — WO disclosed
EP-0538416-B1 SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4 ANTAGONIST ACTIVITY RHONE POULENC RORER INT (US) 1995-08-09 — — EP disclosed
EP-0538416-A4 SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY RHONE POULENC RORER INT (US) 1994-05-18 — — EP disclosed
US-5232948-A SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1993-08-03 — — US disclosed
EP-0538416-A1 SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. RHONE POULENC RORER INT (US) 1993-04-28 — — EP disclosed
WO-1992004315-A1 SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) 1992-03-19 — — WO disclosed
US-4962203-A ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS MERCK FROST CANADA, INC. (CA) 1990-10-09 — — US disclosed
EP-0206751-A2 2-Substituted quinolines, their preparation and use MERCK FROSST CANADA INC. (CA) 1986-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127605-A1 NUCLEIC ACID CONJUGATE NSUN3, NSUN2, RNASEH1 CA1 827/4885CA2 1977/4885CA12 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.